{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:47:01Z","timestamp":1777492021055,"version":"3.51.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>The impact of the coronavirus disease 2019 (COVID\u201019) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resource use among patients with NAFLD admitted with COVID\u201019 by using electronic medical records data for adult patients with COVID\u201019 hospitalized in a multihospital health system who were discharged between March and December 2020. NAFLD was diagnosed by imaging or liver biopsy without other liver diseases. Charlson\u2019s comorbidity index (CCI) and Elixhauser comorbidity index (ECI) scores were calculated. In the study sample, among the 4,835 patients hospitalized for COVID\u201019, 553 had NAFLD (age: 55 \u00b1 16 years, 51% male, 17% White, 11% Black, 58% Hispanic, 8% Asian, 5% from congregated living, 58% obese, 15% morbid obesity [body mass index\u00a0\u2265\u00a040], 51% type 2 diabetes, 63% hypertension, mean [SD] baseline CCI of 3.9 [3.2], and baseline ECI of 13.4 [11.3]). On admission, patients with NAFLD had more respiratory symptoms, higher body temperature and heart rate, higher alanine aminotransferase and aspartate aminotransferase than non\u2010NAFLD controls (n\u00a0=\u00a02,736; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.05). Of the patients with NAFLD infected with COVID\u201019, 3.9% experienced acute liver injury. The NAFLD group had significantly longer length of stay, intensive care unit use, and mechanical ventilation, with a crude inpatient mortality rate of 11%. In multivariate analysis, independent predictors of inpatient mortality among patients with NAFLD infected with COVID\u201019 were older age, morbid obesity, ECI score\u00a0\u2265\u00a011, higher Fibrosis\u20104 Index (FIB\u20104) score, and oxygen saturation &lt;90% (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.05), but not sex, race\/ethnicity, or any individual comorbidity (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&gt;\u00a00.05). <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> Patients with NAFLD infected with COVID\u201019 tend to be sicker on admission and require more hospital resource use. Independent predictors of mortality included higher FIB\u20104 and multimorbidity scores, morbid obesity, older age, and hypoxemia on admission.<\/jats:p>","DOI":"10.1002\/hep4.1802","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T09:41:35Z","timestamp":1626860495000},"page":"3062-3072","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":35,"title":["Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID\u201019 Infection"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Lam","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Cable","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Felix","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Jeffers","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Younossi","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huong","family":"Pham","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manirath","family":"Srishord","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Austin","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Estep","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Terra","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carey","family":"Escheik","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"de Avila","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pegah","family":"Golabi","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Kolacevski","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Racila","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Gerber","sequence":"additional","affiliation":[{"name":"Inova Medicine,Inova Health System,Falls Church,VA,USA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"hep41802-bib-0001-20241104","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep41802-bib-0002-20241104","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple\u2010hit pathogenesis of non\u2010alcoholic fatty liver disease (NAFLD)","volume":"65","year":"2016","journal-title":"Metabolism"},{"key":"hep41802-bib-0003-20241104","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1053\/j.gastro.2007.03.052","article-title":"The epidemiology of obesity","volume":"132","year":"2007","journal-title":"Gastroenterology"},{"key":"hep41802-bib-0004-20241104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1467-789X.2005.00165.x","article-title":"Prevalence of obesity in the United States","volume":"6","year":"2005","journal-title":"Obes Rev"},{"key":"hep41802-bib-0005-20241104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/epirev\/mxm012","article-title":"The global epidemic of obesity: an overview","volume":"29","year":"2007","journal-title":"Epidemiol Rev"},{"key":"hep41802-bib-0006-20241104","first-page":"61","article-title":"The patient perspectives on future therapeutic options in NASH and patient needs","volume":"6","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"hep41802-bib-0007-20241104","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"hep41802-bib-0008-20241104","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD according to the body composition and presence of metabolic abnormalities","volume":"4","year":"2020","journal-title":"Hepatol Commun"},{"key":"hep41802-bib-0009-20241104","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","year":"2020","journal-title":"Gut"},{"key":"hep41802-bib-0010-20241104","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41802-bib-0011-20241104","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep4.1510","article-title":"Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States","volume":"4","year":"2020","journal-title":"Hepatol Commun"},{"key":"hep41802-bib-0012-20241104","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep41802-bib-0013-20241104","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2020.06.006","article-title":"COVID\u201019 and the liver","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep41802-bib-0014-20241104","article-title":"Risk factors related to hepatic injury in patients with corona virus disease 2019","year":"2020","journal-title":"medRxiv"},{"key":"hep41802-bib-0015-20241104","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2010infected pneumonia in Wuhan","volume":"323","year":"2020","journal-title":"JAMA"},{"key":"hep41802-bib-0016-20241104","article-title":"Service Line care delivery model for COVID\u201019 patient\u2010centric care","year":"2021","journal-title":"AJMC"},{"key":"hep41802-bib-0017-20241104","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","year":"1987","journal-title":"J Chronic Dis"},{"key":"hep41802-bib-0018-20241104","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data","volume":"47","year":"2009","journal-title":"Med Care"},{"key":"hep41802-bib-0019-20241104","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M17-2820","article-title":"Prognostic accuracy of the quick sequential organ failure assessment for mortality in patients with suspected infection: a systematic review and meta\u2010analysis","volume":"168","year":"2018","journal-title":"Ann Intern Med"},{"key":"hep41802-bib-0020-20241104","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID\u201019 in the New York city area","volume":"323","year":"2020","journal-title":"JAMA"},{"key":"hep41802-bib-0021-20241104","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis patients with HIV\/HCV co\u2010infection","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep41802-bib-0022-20241104","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12072-018-09926-z","article-title":"Race\/ethnicity\u2010based temporal changes in prevalence of NAFLD\u2010related advanced fibrosis in the United States, 2005\u20102016","volume":"13","year":"2019","journal-title":"Hepatol Int"},{"key":"hep41802-bib-0023-20241104","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta\u2010analysis","volume":"16","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41802-bib-0024-20241104","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"China medical treatment expert group for Covid\u201019. Clinical characteristics of coronavirus disease 2019 in China","volume":"382","year":"2020","journal-title":"N Engl J Med"},{"key":"hep41802-bib-0025-20241104","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jmv.25757","article-title":"COVID\u201019 patients' clinical characteristics, discharge rate, and fatality rate of metaanalysis","volume":"92","year":"2020","journal-title":"J Med Virol"},{"key":"hep41802-bib-0026-20241104","article-title":"In\u2010hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID\u201019","volume":"15","year":"2020","journal-title":"PLoS One"},{"key":"hep41802-bib-0027-20241104","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2020.05.013","article-title":"High mortality rates for SARS\u2010CoV\u20102 infection in patients with pre\u2010existing chronic liver disease and cirrhosis: preliminary results from an international registry","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep41802-bib-0028-20241104","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s12072-020-10078-2","article-title":"Prevalence of chronic liver disease in patients with COVID\u201019 and their clinical outcomes: a systematic review and meta\u2010analysis","volume":"14","year":"2020","journal-title":"Hepatol Int"},{"key":"hep41802-bib-0029-20241104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta\u2010analysis","volume":"71","year":"2019","journal-title":"J Hepatol"},{"key":"hep41802-bib-0030-20241104","article-title":"Impact of chronic liver disease on outcomes of hospitalized patients with COVID\u201019: A multicentre United States experience","year":"2020","journal-title":"Liver Int"},{"key":"hep41802-bib-0031-20241104","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1007\/s11606-019-05340-9","article-title":"Low awareness of nonalcoholic fatty liver disease in a population\u2010based cohort sample: the CARDIA study","volume":"34","year":"2019","journal-title":"J Gen Intern Med"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1802","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:01:26Z","timestamp":1730707286000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1802","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]}}}